Wednesday
Conference/Events
Biotechnology Analyst…
Biotechnology Analyst Biegler, along with Dr. Christos Vaklavas discuss the HR+ metastatic breast cancer landscape, expectations for upcoming initial data for RLY-2608 (PI3Kalpha), unmet need for oral SERD(s), and the impact of Enhertu on the HR+ space (relevant companies RLAY, ARVN, OLMA, AMAM, GILD, AZN, LLY) on an Analyst/Industry conference call to be held on March 27 at 2 pm.
Show Hide Related Items >> <<
12/07/22 Olema announces results from Phase 1b dose escalation study of OP-125 10/26/22 Olema Oncology announces preliminary results from OP-1250 trial $331.02 / +0.015 (+0.00%)
03/22/23 Roche to collaborate with Lilly on early diagnosis of Alzheimer's disease 03/14/23 Veru says terminating Phase 3 VERACITY trial of sabizabulin 03/08/23 Eli Lilly says primary, secondary endpoints not met in A4 Study 03/08/23 Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older 03/21/23 Kite announces primary OS analysis results of Phase 3 ZUMA-7 study 03/20/23 Gilead exercises option to license Nurix's NX-0479 03/20/23 Gilead exercises option to exclusively license NX-0479 from Nurix Therapeutics 02/22/23 Gilead presents PoC data for investigational combination of lenacapavir, bNAbs 03/09/23 AstraZeneca announces ADAURA trial meets secondary endpoint 03/09/23 AstraZeneca announces AEGEAN trial demonstrated statistical significance 03/09/23 AstraZeneca says Tagrisso showed 'strong' overall survival benefit in trial 03/09/23 AstraZeneca says Imfinzi significantly improved event-free survival in AEGEAN 02/23/23 Arvinas expects cash to fund requirements into 2026 12/16/22 Arvinas appoints Everett Cunningham to board of directors 11/22/22 Arvinas says ARV-471 achieves clinical benefit rate of 38% in evaluable patients 11/08/22 Arvinas expects cash to fund operations multiple years beyond 2024 03/07/23 Ambrx Biopharma falls -26.7% 03/07/23 Ambrx Biopharma falls -13.4% 03/07/23 Ambrx Biopharma falls -10.9% 03/06/23 Ambrx Biopharma trading resumes $15.21 / -0.3401 (-2.19%)
03/09/23 Guggenheim Relay Therapeutics price target lowered to $28 from $45 at Guggenheim 03/07/23 H.C. Wainwright Relay Therapeutics price target raised to $46 from $43 at H.C. Wainwright 02/02/23 Oppenheimer Relay Therapeutics initiated with an Outperform at Oppenheimer 01/19/23 JMP Securities Relay Therapeutics price target lowered to $28 from $38 at JMP Securities 03/18/23 Citi Arvinas price target raised to $77 from $72 at Citi 02/23/23 Capital One Arvinas remains one of the best biotechs to own, says Capital One 01/17/23 Truist Arvinas price target lowered to $65 from $100 at Truist 01/12/23 Capital One Arvinas pullback a buying opportunity, says Capital One 03/10/23 H.C. Wainwright Olema Oncology price target raised to $15 from $12 at H.C. Wainwright 02/22/23 Credit Suisse Olema Oncology initiated with an Outperform at Credit Suisse 07/06/22 Canaccord Olema Oncology assumed with a Buy at Canaccord 06/09/22 H.C. Wainwright H.C. Wainwright upgrades Olema to Buy after 'huge positive' in data 03/03/23 Baird Ambrx Biopharma price target raised to $11 from $4 at Baird 10/19/22 Baird Ambrx Biopharma price target lowered to $4 from $8 at Baird 09/21/22 Baird Ambrx Biopharma price target lowered to $8 from $16 at Baird 04/07/22 Baird Baird starts Ambrx Biopharma with Outperform, $16 price target 03/20/23 Oppenheimer Oppenheimer reiterates Outperform on Nurix Therapeutics following Gilead news 03/13/23 Stifel Arcellx initiated with a Buy at Stifel 02/14/23 Mizuho Gilead price target raised to $101 from $88 at Mizuho 02/10/23 TD Cowen Gilead price target raised to $95 from $90 at Cowen 03/15/23 Berenberg AstraZeneca price target lowered to 124 GBp from 126 GBp at Berenberg 03/07/23 Guggenheim Guggenheim starts Mineralys at Buy, sees multibillion-dollar potential for ASIs 03/07/23 Evercore ISI Mineralys Therapeutics initiated with an Outperform at Evercore ISI 02/21/23 UBS AstraZeneca price target raised to 11,900 GBp from 10,100 GBp at UBS $331.02 / +0.015 (+0.00%)
03/22/23 Stifel Stifel argues sympathy trading not a predictor for Viking's pending VK2735 data 03/17/23 Stifel Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class' 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo $15.21 / -0.3401 (-2.19%)
11/03/22 Relay Therapeutics reports Q3 EPS (76c), consensus (71c) 03/09/23 Olema Oncology reports Q4 EPS (65c), consensus (65c) $331.02 / +0.015 (+0.00%)
03/09/23 Precision BioSciences reports Q4 EPS (26c), consensus (21c) 02/02/23 Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30 02/02/23 Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78 02/01/23 Notable companies reporting before tomorrow's open 02/02/23 Gilead sees FY23 adjusted EPS $6.60-$7.00, consensus $6.73 02/02/23 Gilead reports Q4 adjusted EPS $1.67, consensus $1.49 02/02/23 Notable companies reporting after market close 12/20/22 Gilead expects Tmunity acquisition to reduce FY23 EPS by 18c-22c 02/09/23 AstraZeneca sees FY23 core EPS up high single to low double-digit percentage 02/09/23 AstraZeneca reports Q4 core EPS $1.38, consensus $1.35 11/10/22 AstraZeneca raises FY22 core EPS view to high 20s to low 30s percentage 11/10/22 AstraZeneca reports Q3 core EPS $1.67, YTD core EPS $5.28 02/23/23 Arvinas reports Q4 EPS ($1.56), consensus ($1.22) 11/08/22 Arvinas reports Q3 EPS ($1.24), consensus ($1.13)
Recommendations
Viking Therapeutics…
Viking Therapeutics (VKTX) shares traded down ~20% following the Phase 2 interim data of pemvidutide announced by Altimmune (ALT), a competing GLP-1/glucagon program in obesity, Stifel tells investors in a research note. The firm believes this reaction is undeserved due to it being a different compound altogether. Further, Stifel argues a better benchmark for comparison is Eli Lilly's (LLY) Mounjaro. Viking's VK2735 is approaching Phase 1b SAD/MAD data before the end of Q1, which the firm believes will serve to set safety/tolerability expectations and elucidate points of differentiation. Stifel reiterated a Buy rating and a $22 price target on the stock.
Show Hide Related Items >> <<
01/09/23 Viking Therapeutics completes enrollment in Phase 2b VOYAGE study of VK2809 01/02/23 Ascletis says Viking Therapeutics complaints 'have no merit' 12/19/22 Viking Therapeutics up 58% after Madrigal announces NASH trial data 03/22/23 Roche to collaborate with Lilly on early diagnosis of Alzheimer's disease 03/14/23 Veru says terminating Phase 3 VERACITY trial of sabizabulin 03/08/23 Eli Lilly says primary, secondary endpoints not met in A4 Study 03/08/23 Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older 03/21/23 Altimmune falls 35% to $7.15 after initerim MOMENTUM Phase 2 trial data 03/21/23 Altimmune announces reuslts from interim analysis of MOMENTUM Phase 2 trial 01/04/23 Altimmune appoints Jordt as Chief Business Officer 12/20/22 Altimmune announces topline results from 24-week trial of pemvidutide 03/21/23 William Blair William Blair says Viking bull thesis intact after Altimmune data 03/16/23 Stifel Viking Therapeutics initiated with a Buy at Stifel 02/23/23 Oppenheimer Viking Therapeutics price target raised to $20 from $17 at Oppenheimer 01/16/23 Piper Sandler Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler 03/21/23 Goldman Sachs Altimmune downgraded to Neutral from Buy at Goldman Sachs 03/21/23 H.C. Wainwright Altimmune attractive after 'overdone' selloff, says H.C. Wainwright 03/21/23 H.C. Wainwright Altimmune selloff on weight loss data overdone, says H.C. Wainwright 03/17/23 Stifel Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class' 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo 03/09/23 JPMorgan Eli Lilly weakness brings attractive entry point, says JPMorgan 02/08/23 Viking Therapeutics reports Q4 EPS (26c), consensus (23c) 10/26/22 Viking Therapeutics reports Q3 EPS (21c), consensus (23c) 03/09/23 Precision BioSciences reports Q4 EPS (26c), consensus (21c) 02/02/23 Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30 02/02/23 Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78 02/01/23 Notable companies reporting before tomorrow's open 02/28/23 Altimmune reports Q4 EPS (43c), consensus (50c) 11/10/22 Altimmune reports Q3 EPS (48c), consensus (50c) 01/02/23 Viking sued Ascletis alleging stolen trade secrets, Reuters reports 03/06/23 New diabetes drugs altering how patients are treated, WSJ reports 12/19/22 Eli Lilly's Mounjaro, Trulicity added to FDA shortage list, STATNews reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 10/11/22 New quality issues found at Eli Lilly drug plant, Reuters reports 12/21/22 Biotech Alert: Searches spiking for these stocks today 12/19/22 Trial success is rocketing this NASH stock higher and sinking these peers 03/13/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 What You Missed On Wall Street On Thursday 03/22/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/21/23 What You Missed On Wall Street On Tuesday 03/21/23 What You Missed On Wall Street This Morning 12/20/22 Fly Intel: Pre-market Movers 03/21/23 Viking Therapeutics call volume above normal and directionally bullish 03/16/23 Viking Therapeutics call volume above normal and directionally bullish 03/08/23 Viking Therapeutics call volume above normal and directionally bullish 02/17/23 Viking Therapeutics call volume above normal and directionally bullish 03/13/23 Early notable gainers among liquid option names on March 13th 03/10/23 Early notable gainers among liquid option names on March 10th 11/01/22 Unusually active option classes on open November 1st 10/03/22 Eli Lilly And Co put volume heavy and directionally bearish 03/20/23 Altimmune put volume heavy and directionally bearish 03/09/23 Altimmune call volume above normal and directionally bullish 03/08/23 Altimmune call volume above normal and directionally bullish 03/03/23 Altimmune call volume above normal and directionally bullish
Hot Stocks
Roche (RHHBY) announced…
Roche (RHHBY) announced that it has entered into a collaboration with Eli Lilly (LLY) to support the development of Roche's Elecsys Amyloid Plasma Panel, or EAPP, which it calls "an innovative blood test that aims to facilitate the earlier diagnosis of Alzheimer's disease." Roche said: "Today, barriers to early and accurate diagnosis of Alzheimer's exist across the globe with up to 75% of people living with the symptoms of Alzheimer's, but without a diagnosis. Those who have received a diagnosis waited, on average, 2.8 years after symptom onset. To address the growing strain that Alzheimer's is putting on healthcare systems, it will be essential to make a person's journey to diagnosis faster and more accessible. This will ultimately enable access to appropriate new therapies as they become available. This collaboration is aligned to both Roche and Lilly's shared objective to support patients by improving the journey to a timely and accurate diagnosis and treatment. If approved, the EAPP test would be an additional tool to identify low likelihood of amyloid pathology in symptomatic patients and determine whether they should proceed to further evaluation and testing that may confirm a diagnosis."
Show Hide Related Items >> <<
03/20/23 Genentech announces long-term data for Evrysdi in SUNFISH study 03/09/23 FDA AdCom votes in favor of Genentech's Polivy combination in DLBCL 03/06/23 Roche announces FDA approval of VENTANA PD-L1 Assay 02/28/23 Roche expands collaboration with CDC to strengthen laboratory capabilities 03/14/23 Veru says terminating Phase 3 VERACITY trial of sabizabulin 03/08/23 Eli Lilly says primary, secondary endpoints not met in A4 Study 03/08/23 Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older 03/03/23 Eli Lilly says FDA broadens indication for Verzenio 03/16/23 Needham Recursion Pharmaceuticals initiated with a Buy at Needham 02/27/23 Societe Generale Societe Generale upgrades Roche to Buy, says 'enough is enough' 02/27/23 Societe Generale Roche upgraded to Buy from Hold at Societe Generale 02/15/23 JMP Securities iBio downgraded to Market Perform at JMP on CDMO and IBIO-101 questions 03/17/23 Stifel Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class' 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo 03/09/23 JPMorgan Eli Lilly weakness brings attractive entry point, says JPMorgan 02/02/23 Roche reports FY22 core EPS CHF20.30 vs. CHF19.81 last year 10/18/22 Roche reports nine months group sales CHF 47.04B vs. CHF 46.68B last year 03/09/23 Precision BioSciences reports Q4 EPS (26c), consensus (21c) 02/02/23 Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30 02/02/23 Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78 02/01/23 Notable companies reporting before tomorrow's open 01/11/23 Roche looks internally for pharmaceutical unit chief, Bloomberg reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 03/06/23 New diabetes drugs altering how patients are treated, WSJ reports 12/19/22 Eli Lilly's Mounjaro, Trulicity added to FDA shortage list, STATNews reports 10/11/22 New quality issues found at Eli Lilly drug plant, Reuters reports 01/23/23 Biotech Alert: Searches spiking for these stocks today 01/12/23 Meet ZyVersa: Fly exclusive interview with CEO Stephen Glover 11/21/22 Biotech Alert: Searches spiking for these stocks today 11/16/22 Biotech Alert: Searches spiking for these stocks today 03/13/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 What You Missed On Wall Street On Thursday 03/13/23 Early notable gainers among liquid option names on March 13th 03/10/23 Early notable gainers among liquid option names on March 10th 11/01/22 Unusually active option classes on open November 1st 10/03/22 Eli Lilly And Co put volume heavy and directionally bearish
Over a week ago
Recommendations
Stifel analyst Paul…
Stifel analyst Paul Matteis lowered the firm's price target on Biogen (BIIB) to $324 from $331 and keeps a Buy rating on the shares, telling investors that based on the firm's research ahead of Eli Lilly's (LLY) donanemab TRAILBLAZER-ALZ 2 readout that it is "more confident" that Biogen (BIIB) and Eisai's (ESALY) lecanemab is "best-in-class among late-stage abeta antibodies." The firm now assumes a slower initial ramp to reflect near-term CMS uncertainty, but believes this will "become a blockbuster class" and notes that its Alzheimer's disease market model is now split 60/40 for lecanemab/donanemab.
Show Hide Related Items >> <<
03/14/23 Veru says terminating Phase 3 VERACITY trial of sabizabulin 03/08/23 Eli Lilly says primary, secondary endpoints not met in A4 Study 03/08/23 Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older 03/03/23 Eli Lilly says FDA broadens indication for Verzenio 02/27/23 Biogen license application for lecanemab designated for priority review in China 01/29/23 Eisai, Biogen say lecanemab received Priority Review status in Japan 01/26/23 Eisai, Biogen: EMA accepts MAA for lecanemab for early Alzheimer's disease 03/16/23 Biogen receives favorable court ruling on TECFIDERA 03/14/23 Biogen appoints Triano as Head of Investor Relations 03/13/23 Biogen 'welcomes' VHA recent decision to provide coverage to Leqembi 03/08/23 Biogen elects Dorsa as Chair of the Board of Directors 03/13/23 RBC Capital Biogen price target raised to $350 from $335 at RBC Capital 03/09/23 BofA No ad com suggests positive potential outcome for Sage's zura, says BofA 02/16/23 RBC Capital Biogen price target lowered to $333 from $359 at RBC Capital 02/16/23 TD Cowen Biogen price target raised to $315 from $300 at Cowen 01/20/23 William Blair Donanemab CRL a 'positive headline' for Biogen's Leqembi, says William Blair 12/02/22 JonesResearch Anavex price target raised to $80 from $40 at JonesTrading 11/30/22 Mizuho Mizuho says Biogen not mentioned in 90 minute lecanemab presentation 11/30/22 Jefferies Biogen price target raised to $350 from $325 at Jefferies 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo 03/09/23 JPMorgan Eli Lilly weakness brings attractive entry point, says JPMorgan 03/06/23 Jefferies Jefferies starts 'priced to perfection' Eli Lilly with a Hold 03/09/23 Precision BioSciences reports Q4 EPS (26c), consensus (21c) 02/02/23 Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30 02/02/23 Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78 02/01/23 Notable companies reporting before tomorrow's open 02/15/23 Biogen sees FY23 EPS $15.00-$16.00, consensus $15.72 02/15/23 Biogen reports Q4 EPS $4.05, consensus $3.48 02/14/23 Notable companies reporting before tomorrow's open 03/06/23 New diabetes drugs altering how patients are treated, WSJ reports 12/19/22 Eli Lilly's Mounjaro, Trulicity added to FDA shortage list, STATNews reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 10/11/22 New quality issues found at Eli Lilly drug plant, Reuters reports 10/28/22 Investigator in Alzheimer's trial linked lecanemab to patient death, STAT says 03/13/23 VA to widely cover new Alzheimer's treatment from Eisai and Biogen, STAT says 01/11/23 FDA Commissioner defends FDA's approval of Biogen's Aduhelm, WSJ reports 12/23/22 Third trial death tied to Biogen and Eisai Alzheimer's drug, Science reports 11/28/22 Second death linked to Eisai's lecanemab Alzheimer's drug, Science says 03/13/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 What You Missed On Wall Street On Thursday 01/06/23 What You Missed On Wall Street On Friday 11/30/22 Fly Intel: Pre-market Movers 11/28/22 Fly Intel: Pre-market Movers 09/28/22 What You Missed On Wall Street On Wednesday 02/15/23 What You Missed On Wall Street On Wednesday 02/15/23 What You Missed On Wall Street This Morning 02/15/23 Fly Intel: Pre-market Movers 01/20/23 Fly Intel: Pre-market Movers 03/13/23 Early notable gainers among liquid option names on March 13th 03/10/23 Early notable gainers among liquid option names on March 10th 11/01/22 Unusually active option classes on open November 1st 10/03/22 Eli Lilly And Co put volume heavy and directionally bearish 11/30/22 Early notable gainers among liquid option names on November 30th 11/14/22 Early notable gainers among liquid option names on November 14th 10/13/22 Early notable gainers among liquid option names on October 13th 09/29/22 Unusually active option classes on open September 29th
Conference/Events
Healthcare/Neuroscience…
Healthcare/Neuroscience Analysts, along with Dr. Anton Porsteinsson, in conjunction with Needham's Virtual Neuroscience Forum and provide a commercial update of BIIB's Leqembi, discuss the upcoming TRAILBLAZER-ALZ 2 data readout for LLY's donanemab on an Analyst/Industry conference call to be held on March 15 at 12:15 pm.
Show Hide Related Items >> <<
03/14/23 Veru says terminating Phase 3 VERACITY trial of sabizabulin 03/08/23 Eli Lilly says primary, secondary endpoints not met in A4 Study 03/08/23 Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older 03/03/23 Eli Lilly says FDA broadens indication for Verzenio 03/14/23 Biogen appoints Triano as Head of Investor Relations 03/13/23 Biogen 'welcomes' VHA recent decision to provide coverage to Leqembi 03/08/23 Biogen elects Dorsa as Chair of the Board of Directors 03/08/23 Biogen, Sage Therapeutics: FDA has no plans to discuss NDA for zuranolone 03/13/23 RBC Capital Biogen price target raised to $350 from $335 at RBC Capital 03/09/23 BofA No ad com suggests positive potential outcome for Sage's zura, says BofA 02/16/23 RBC Capital Biogen price target lowered to $333 from $359 at RBC Capital 02/16/23 TD Cowen Biogen price target raised to $315 from $300 at Cowen 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo 03/09/23 JPMorgan Eli Lilly weakness brings attractive entry point, says JPMorgan 03/06/23 Jefferies Jefferies starts 'priced to perfection' Eli Lilly with a Hold 03/09/23 Precision BioSciences reports Q4 EPS (26c), consensus (21c) 02/02/23 Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30 02/02/23 Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78 02/01/23 Notable companies reporting before tomorrow's open 02/15/23 Biogen sees FY23 EPS $15.00-$16.00, consensus $15.72 02/15/23 Biogen reports Q4 EPS $4.05, consensus $3.48 02/14/23 Notable companies reporting before tomorrow's open 03/06/23 New diabetes drugs altering how patients are treated, WSJ reports 12/19/22 Eli Lilly's Mounjaro, Trulicity added to FDA shortage list, STATNews reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 10/11/22 New quality issues found at Eli Lilly drug plant, Reuters reports 03/13/23 VA to widely cover new Alzheimer's treatment from Eisai and Biogen, STAT says 01/11/23 FDA Commissioner defends FDA's approval of Biogen's Aduhelm, WSJ reports 12/23/22 Third trial death tied to Biogen and Eisai Alzheimer's drug, Science reports 11/28/22 Second death linked to Eisai's lecanemab Alzheimer's drug, Science says 03/13/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 What You Missed On Wall Street On Thursday 02/15/23 What You Missed On Wall Street On Wednesday 02/15/23 What You Missed On Wall Street This Morning 02/15/23 Fly Intel: Pre-market Movers 01/20/23 Fly Intel: Pre-market Movers 03/13/23 Early notable gainers among liquid option names on March 13th 03/10/23 Early notable gainers among liquid option names on March 10th 11/01/22 Unusually active option classes on open November 1st 10/03/22 Eli Lilly And Co put volume heavy and directionally bearish 11/30/22 Early notable gainers among liquid option names on November 30th 11/14/22 Early notable gainers among liquid option names on November 14th 10/13/22 Early notable gainers among liquid option names on October 13th 09/29/22 Unusually active option classes on open September 29th
Conference/Events
Healthcare/Neuroscience…
Healthcare/Neuroscience Analysts, along with Dr. Anton Porsteinsson, in conjunction with Needham's Virtual Neuroscience Forum and provide a commercial update of BIIB's Leqembi, discuss the upcoming TRAILBLAZER-ALZ 2 data readout for LLY's donanemab on an Analyst/Industry conference call to be held on March 15 at 12:15 pm.
Show Hide Related Items >> <<
03/14/23 Veru says terminating Phase 3 VERACITY trial of sabizabulin 03/08/23 Eli Lilly says primary, secondary endpoints not met in A4 Study 03/08/23 Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older 03/03/23 Eli Lilly says FDA broadens indication for Verzenio 03/14/23 Biogen appoints Triano as Head of Investor Relations 03/13/23 Biogen 'welcomes' VHA recent decision to provide coverage to Leqembi 03/08/23 Biogen elects Dorsa as Chair of the Board of Directors 03/08/23 Biogen, Sage Therapeutics: FDA has no plans to discuss NDA for zuranolone 03/13/23 RBC Capital Biogen price target raised to $350 from $335 at RBC Capital 03/09/23 BofA No ad com suggests positive potential outcome for Sage's zura, says BofA 02/16/23 RBC Capital Biogen price target lowered to $333 from $359 at RBC Capital 02/16/23 TD Cowen Biogen price target raised to $315 from $300 at Cowen 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo 03/09/23 JPMorgan Eli Lilly weakness brings attractive entry point, says JPMorgan 03/06/23 Jefferies Jefferies starts 'priced to perfection' Eli Lilly with a Hold 03/09/23 Precision BioSciences reports Q4 EPS (26c), consensus (21c) 02/02/23 Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30 02/02/23 Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78 02/01/23 Notable companies reporting before tomorrow's open 02/15/23 Biogen sees FY23 EPS $15.00-$16.00, consensus $15.72 02/15/23 Biogen reports Q4 EPS $4.05, consensus $3.48 02/14/23 Notable companies reporting before tomorrow's open 03/06/23 New diabetes drugs altering how patients are treated, WSJ reports 12/19/22 Eli Lilly's Mounjaro, Trulicity added to FDA shortage list, STATNews reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 10/11/22 New quality issues found at Eli Lilly drug plant, Reuters reports 03/13/23 VA to widely cover new Alzheimer's treatment from Eisai and Biogen, STAT says 01/11/23 FDA Commissioner defends FDA's approval of Biogen's Aduhelm, WSJ reports 12/23/22 Third trial death tied to Biogen and Eisai Alzheimer's drug, Science reports 11/28/22 Second death linked to Eisai's lecanemab Alzheimer's drug, Science says 03/13/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 What You Missed On Wall Street On Thursday 02/15/23 What You Missed On Wall Street On Wednesday 02/15/23 What You Missed On Wall Street This Morning 02/15/23 Fly Intel: Pre-market Movers 01/20/23 Fly Intel: Pre-market Movers 03/13/23 Early notable gainers among liquid option names on March 13th 03/10/23 Early notable gainers among liquid option names on March 10th 11/01/22 Unusually active option classes on open November 1st 10/03/22 Eli Lilly And Co put volume heavy and directionally bearish 11/30/22 Early notable gainers among liquid option names on November 30th 11/14/22 Early notable gainers among liquid option names on November 14th 10/13/22 Early notable gainers among liquid option names on October 13th 09/29/22 Unusually active option classes on open September 29th
Hot Stocks
In a regulatory filing,…
In a regulatory filing, Veru stated that on March 14, at the Oppenheimer 33rd Annual Healthcare Conference, Dr. Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of the company, presented Veru's updated strategy as part of the company's ongoing effort to refocus its drug development efforts on those drug candidates which it believes have the best opportunity to lead to long-term success and shareholder value creation and conserve cash, including a reduction in personnel and certain other measures to reduce costs. "The presentation included a description of Veru's refocused research and development strategy which includes the following: (i) plans for continued development of sabizabulin in Phase 3 COVID-19 confirmatory study in hospitalized moderate to severe COVID-19 patients at high risk for acute respiratory disease syndrome, or 'ARDS,' and planned development of sabizabulin in Phase 3 clinical study in hospitalized influenza patients at high risk for ARDS, (ii) plans for an updated ongoing Phase 3 study of enobosarm and abemaciclib combination in the second line setting for AR+ ER+ HER2- metastatic breast cancer patients, into which Veru plans to roll the current ARTEST study, if agreed by the U.S. Food and Drug Administration and the company's clinical trial partner, Eli Lilly & Company (LLY), and (iii) a planned Phase 3 study of enobosarm in bone-only non-measurable metastatic ER+ HER2- breast cancer. In addition, Dr. Steiner announced that Veru is reserving sabizabulin for clinical development only in infectious disease indications, and accordingly, terminating the Phase 3 VERACITY trial of sabizabulin in certain prostate cancer patients. Further, Phase 2 development of the Veru-100 and zuclomiphene assets will be paused. On March 2, 2023, Veru had announced that the FDA declined to grant at this time Veru's request for Emergency Use Authorization for sabizabulin to treat hospitalized adult patients with moderate to severe COVID-19 who are at high risk for ARDS," the filing stated.
Show Hide Related Items >> <<
03/02/23 Veru announces FDA comments on Phase 3 study protocol 03/02/23 Veru announces FDA declines to grant EUA for sabizabulin 01/10/23 Veru appoints David Ho as chairman of Scientific Advisory Board 11/09/22 Veru announces update on FDA AdCom meeting on Sabizabulin as COVID treatment 03/08/23 Eli Lilly says primary, secondary endpoints not met in A4 Study 03/08/23 Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older 03/03/23 Eli Lilly says FDA broadens indication for Verzenio 03/01/23 Eli Lilly cuts insulin prices by 70%, caps out of pocket costs 02/14/23 Oppenheimer Veru price target lowered to $14 from $20 at Oppenheimer 02/10/23 H.C. Wainwright Veru price target lowered to $14 from $18 at H.C. Wainwright 12/07/22 H.C. Wainwright Veru price target lowered to $18 from $21 at H.C. Wainwright 11/10/22 H.C. Wainwright Veru price target lowered to $21 from $24 at H.C. Wainwright 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo 03/09/23 JPMorgan Eli Lilly weakness brings attractive entry point, says JPMorgan 03/06/23 Jefferies Jefferies starts 'priced to perfection' Eli Lilly with a Hold 02/09/23 Veru reports Q1 EPS (46c), consensus (38c) 12/05/22 Veru reports Q4 EPS (51c), consensus (30c) 03/09/23 Precision BioSciences reports Q4 EPS (26c), consensus (21c) 02/02/23 Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30 02/02/23 Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78 02/01/23 Notable companies reporting before tomorrow's open 03/06/23 New diabetes drugs altering how patients are treated, WSJ reports 12/19/22 Eli Lilly's Mounjaro, Trulicity added to FDA shortage list, STATNews reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 10/11/22 New quality issues found at Eli Lilly drug plant, Reuters reports 03/03/23 What You Missed On Wall Street On Friday 03/03/23 What You Missed On Wall Street This Morning 02/09/23 What You Missed On Wall Street On Thursday 02/09/23 What You Missed On Wall Street This Morning 03/13/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 What You Missed On Wall Street On Thursday 03/14/23 Largest borrow rate increases among liquid names 01/20/23 Veru call volume above normal and directionally bullish 01/10/23 Veru call volume above normal and directionally bullish 01/10/23 Unusually active option classes on open January 10th 03/13/23 Early notable gainers among liquid option names on March 13th 03/10/23 Early notable gainers among liquid option names on March 10th 11/01/22 Unusually active option classes on open November 1st 10/03/22 Eli Lilly And Co put volume heavy and directionally bearish
On The Fly
Want to get stock-moving…
Show Hide Related Items >> <<
02/08/23 Under Armour expects macroeconomic backdrop to remain uneven in 2023 12/21/22 Under Armour names Stephanie Linnartz as CEO 12/21/22 Marriott president Stephanie Linnartz leaving to become CEO of Under Armour 11/18/22 Adtalem Global Education appoints Blake Simpson as CCO 03/06/23 Tesla issues recall notice for 3,470 Model Y vehicles in U.S. 02/27/23 Tesla temporarily halts FSD beta software installations until recall addressed 02/24/23 SEC says Elon Musk still needs lawyer to approve tweets 02/22/23 Tesla to announce move to 'California Engineering Headquarters' 03/13/23 Fisker says no cash deposits, securities at SVB Financial 03/13/23 Marathon Digital reports $142M cash deposits at Signature Bank 03/13/23 MAIA Biotechnology reports no exposure to Silicon Valley Bank 03/13/23 BTCS reports amount equal to FDIC-insured limit of $250K at Signature Bank 03/13/23 NewtekOne provides update on financial holding company transition, forecasts 03/13/23 Iris Energy confirms no deposits with SVB, Signature Bank or Silvergate Capital 02/01/23 PNC Financial raises prime lending rate to 7.75%, effective February 2 01/27/23 Atlantic Union Bankshares names Matt Linderman as chief information officer 01/18/23 PNC Financial expects to continue share repurchases at 'reduced rate' vs. 2022 01/18/23 PNC Financial says well capitalized with flexibility 01/17/23 Prosperity Bancshares announces roughly 4.6M share buyback 10/19/22 Prosperity Bancshares increases quarterly dividend 5.77% to 55c per share 10/11/22 Prosperity Bancshares to acquire First Bancshares of Texas 10/11/22 Prosperity Bancshares to acquire Lone Star State Bancshares 01/24/23 Orion Engineered invests $60M to reduce emissions, upgrade cogeneration system 11/04/22 Orion Engineered rises 15.9% 11/04/22 Orion Engineered announces $50M share repurchase program 03/08/23 Nuvei sees 20%+ annual y-o-y revenue growth in medium-term 02/22/23 Nuvei expects total volume, revenue, adjusted EBITDA to be in line with outlook 02/22/23 Nuvei completes $1.3B acquisition of Paya Holdings 02/13/23 Nuvei, Mercedes-AMG PETRONAS Formula One Team enter partnership 02/23/23 Nikola provides 2023 outlook 02/22/23 Nikola, E.ON and Richter Group sign collaboration agreement 02/22/23 Nikola selects PlusDrive for Nikola Tre BEV, hydrogen EV in U.S. 02/21/23 Nikola announces additional HYLA brand refueling station in California 03/10/23 Merck says Phase 2/3 CCTG IND.227/KEYNOTE-483 trial met primary endpoint 03/08/23 Opko Health enters exclusive worldwide license agreement with Merck 03/06/23 Merck says MK-0616 'significantly reduced' LDL-C in Phase 2b study 03/06/23 Merck: FDA approves IM route of administration for MMRV family of vaccines 02/21/23 Lam Research announces new executive appointments 01/25/23 Lam Research announces restructuring, 7% workforce reduction 12/11/22 Fly Intel: Top five weekend stock stories 11/16/22 Wafer Fab Equipment names slide after Micron cuts wafer starts $327.00 / +12.055 (+3.83%)
03/08/23 Eli Lilly says primary, secondary endpoints not met in A4 Study 03/08/23 Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older 03/03/23 Eli Lilly says FDA broadens indication for Verzenio 03/01/23 Eli Lilly cuts insulin prices by 70%, caps out of pocket costs $132.32 / -1.335 (-1.00%)
03/08/23 Gemini says JPMorgan relationship 'remains intact' despite reporting 02/23/23 JPMorgan CEO: Inflation 'so insidious' it could hurt growth for 10 years 02/23/23 JPMorgan CEO: It's possible interest rates could hit 6% 03/12/23 Fly Intel: Top five weekend stock stories 03/02/23 GE HealthCare, Advantus Health in pact to provide HTM services 03/01/23 GE HealthCare completes recruitment in manganese-based MRI contrast agent study 02/09/23 GE HealthCare to acquire Caption Health, terms undisclosed 03/06/23 Cabot to establish new technology center in Munster 03/01/23 Amgen to present new Repatha combined data from Phase 3 FOURIER trials 02/02/23 Amgen's Tezspire approved in U.S. for self-administration in severe asthma 01/31/23 Amgen, Horizon Therapeutics receive second request for additional info from FTC 01/31/23 Amgen sees FY23 CapEx about $925M $126.90 / -1.165 (-0.91%)
02/28/23 Advance Auto Parts says Greco to retire as president and CEO at year-end 11/16/22 Advance Auto Parts falls -17.0% 11/16/22 Advance Auto Parts falls -14.6% 11/15/22 Advance Auto Parts falls 10% after Q3 results miss estimates, FY22 EPS view cut 03/13/23 Wolfe Research Tesla downgraded to Peer Perform from Outperform at Wolfe Research 03/09/23 Morgan Stanley Morgan Stanley questions if Tesla has 'outgrown the Cybertruck' 03/08/23 Citi Tesla comments 'very bullish' for lithium industry, says Citi 03/08/23 Berenberg Tesla downgraded to Hold from Buy at Berenberg 03/13/23 JPMorgan Nuvei reinstated with an Overweight at JPMorgan 03/09/23 CIBC Nuvei upgraded to Outperformer at CIBC following better than expected outlook 03/09/23 CIBC Nuvei upgraded to Outperformer from Neutral at CIBC 03/09/23 Raymond James Nuvei price target raised to $49 from $40 at Raymond James 03/13/23 Credit Suisse Orion Engineered initiated with an Outperform at Credit Suisse 03/13/23 Credit Suisse Cabot initiated with an Outperform at Credit Suisse 02/13/23 Loop Capital Cabot price target raised to $113 from $98 at Loop Capital 02/13/23 JPMorgan Cabot price target raised to $87 from $80 at JPMorgan 11/16/22 Deutsche Bank Cabot upgraded to Buy from Hold at Deutsche Bank 03/13/23 Evercore ISI GE HealthCare initiated with an Outperform at Evercore ISI 03/06/23 BofA General Electric price target raised to $96 at BofA ahead of investor day 02/17/23 Mizuho GE HealthCare initiated with a Buy at Mizuho 01/25/23 BofA General Electric price target raised to $92 from $85 at BofA 03/13/23 Morgan Stanley Nikola initiated with an Equal Weight at Morgan Stanley 02/24/23 Deutsche Bank Nikola price target lowered to $3 from $5 at Deutsche Bank 02/24/23 TD Cowen Nikola price target lowered to $5 from $10 at Cowen 01/17/23 BTIG Nikola price target lowered to $5 from $7 at BTIG 03/13/23 DA Davidson DA Davidson upgrades Prosperity Bancshares to Buy on 'great defensive' qualities 03/13/23 Morgan Stanley Fed's new funding program a positive for Charles Schwab, says Morgan Stanley 03/13/23 BofA Charles Schwab price target lowered to $60 from $74 at BofA 03/13/23 Oppenheimer Coinbase price target lowered to $70 from $84 at Oppenheimer 03/13/23 Citi Citi cuts Bill target but says risk/reward favorable after selloff 03/13/23 BofA BofA removes rating on First Republic after SVB, Signature failures 03/13/23 JPMorgan Under Armour downgraded to Neutral from Overweight at JPMorgan 02/09/23 Morgan Stanley Under Armour price target raised to $10 from $8 at Morgan Stanley 02/09/23 Citi Under Armour price target lowered to $12 from $13 at Citi 02/06/23 Deutsche Bank Under Armour price target raised to $14 from $11 at Deutsche Bank $126.90 / -1.165 (-0.91%)
03/13/23 Argus Advance Auto Parts cut to Hold at Argus on flat margins, paused buybacks 03/13/23 Argus Advance Auto Parts downgraded to Hold from Buy at Argus 03/01/23 DA Davidson Advance Auto Parts price target lowered to $142 from $170 at DA Davidson 03/01/23 Raymond James Advance Auto Parts price target lowered to $180 from $200 at Raymond James 03/13/23 Bernstein Lam Research downgraded to Market Perform from Outperform at Bernstein 03/09/23 Citi Citi says HDD storage prices ticking up 03/01/23 KGI Securities Lam Research upgraded to Outperform from Neutral at KGI Securities 01/31/23 Citi Citi opens 'positive catalyst watch' on Lam Research 03/13/23 Wells Fargo Merck downgraded at Wells Fargo on valuation, lack of catalysts 03/13/23 Wells Fargo Merck downgraded to Equal Weight from Overweight at Wells Fargo 03/10/23 Berenberg Merck price target raised to $130 from $125 at Berenberg 03/09/23 Guggenheim Merck price target raised to $123 from $116 at Guggenheim 03/13/23 DA Davidson Prosperity Bancshares upgraded to Buy from Neutral at DA Davidson 03/13/23 Janney Montgomery Scott Prosperity Bancshares upgraded to Buy from Neutral at Janney Montgomery Scott 03/10/23 Morgan Stanley SVB Financial pressures 'highly idiosyncratic,' says Morgan Stanley 03/13/23 Citi PNC Financial upgraded to Buy from Neutral at Citi 02/15/23 Piper Sandler PNC Financial price target raised to $164 from $150 at Piper Sandler 01/19/23 Baird PNC Financial price target lowered to $205 from $210 at Baird 01/19/23 Credit Suisse PNC Financial price target lowered to $165 from $170 at Credit Suisse 03/13/23 Wells Fargo Wells Fargo upgrades Amgen to Overweight, lowers target to $265 03/13/23 Wells Fargo Amgen upgraded to Overweight from Equal Weight at Wells Fargo 02/13/23 Truist Amgen price target lowered to $260 from $280 at Truist 02/06/23 Argus Amgen price target lowered to $270 from $300 at Argus $327.00 / +12.055 (+3.83%)
03/13/23 Wells Fargo Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo 03/09/23 JPMorgan Eli Lilly weakness brings attractive entry point, says JPMorgan 03/06/23 Jefferies Jefferies starts 'priced to perfection' Eli Lilly with a Hold $132.32 / -1.335 (-1.00%)
03/13/23 Wells Fargo Wells Fargo upgrades JPMorgan on 'Goliath is Winning' theme 03/13/23 Wells Fargo JPMorgan upgraded to Overweight from Equal Weight at Wells Fargo 02/24/23 Morgan Stanley JPMorgan price target raised to $173 from $167 at Morgan Stanley 02/08/23 Keefe Bruyette Keefe Bruyette downgrades 'vulnerable' Bank of America to Underperform 02/08/23 Under Armour raises FY23 adjusted EPS view to 52c-56c from 44c-48c 02/08/23 Under Armour reports Q3 adjusted EPS 16c, consensus 9c 02/07/23 Notable companies reporting before tomorrow's open 03/02/23 Aehr Test Systems reiterates annual guidance, comments on Tesla statements 01/25/23 Tesla reports Q4 EPS $1.19, consensus $1.13 01/25/23 Notable companies reporting after market close 10/19/22 Tesla reports Q3 EPS $1.05, consensus 99c 03/10/23 Compugen considers exposure to SVB Financial as immaterial 01/19/23 SVB Financial reports Q4 EPS $4.62, consensus $5.27 10/20/22 SVB Financial reports Q3 EPS $7.21, consensus $6.95 01/17/23 Silvergate Capital reports Q4 adjusted EPS 48c, consensus 81c 10/18/22 Silvergate Capital reports Q3 EPS $1.28, consensus $1.38 01/18/23 PNC Financial sees FY23 revenue up 6%-8% y/y, consensus $23.28B 01/18/23 PNC Financial sees Q1 revenue down about 3% vs. 4Q22, consensus $5.69B 01/18/23 PNC Financial reports Q4 adjusted EPS $3.49, consensus $3.95 01/17/23 Notable companies reporting before tomorrow's open 01/25/23 Prosperity Bancshares reports Q4 EPS $1.51, consensus $1.49 10/26/22 Prosperity Bancshares reports Q3 EPS $1.49, consensus $1.49 02/16/23 Orion Engineered sees FY23 adjusted EPS $2.30-$2.60, consensus $2.55 02/16/23 Orion Engineered reports Q4 adjusted EPS 23c, consensus 17c 11/03/22 Orion Engineered cuts FY22 EPS view to $1.75-$1.90 from $2.00-$2.35 11/03/22 Orion Engineered Carbons reports Q3 adjusted EPS 57c, consensus 56c 03/08/23 Nuvei sees 2023 revenue $1.224B-$1.264B, consensus $973.4M 03/08/23 Nuvei sees Q1 revenue $248M-$256M, consensus $218.97M 03/08/23 Nuvei reports Q4 adjusted EPS 47c, consensus 41c 11/03/22 Nuvei reaffirms FY22 revenue view $820M-$850M, consensus $837.54M 02/23/23 Nikola reports Q4 adjusted EPS (37c), consensus (43c) 02/22/23 Notable companies reporting before tomorrow's open 11/03/22 Nikola reports Q3 adjusted EPS (28c), consensus (39c) 02/28/23 NGM Biopharmaceuticals reports Q4 EPS (45c), consensus (51c) 02/02/23 Merck sees FY23 adjusted EPS $6.80-$6.95, consensus $7.36 02/02/23 Merck reports Q4 adjusted EPS $1.62, consensus $1.54 02/01/23 Notable companies reporting before tomorrow's open 01/25/23 Lam Research sees March quarter adjusted EPS $6.50 +/- 75c, consensus $7.88 01/25/23 Lam Research reports December quarter EPS $10.71, consensus $9.96 10/19/22 Lam Research sees Q2 EPS $10.00 +/- 75c, consensus $9.47 $327.00 / +12.055 (+3.83%)
03/09/23 Precision BioSciences reports Q4 EPS (26c), consensus (21c) 02/02/23 Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30 02/02/23 Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78 $132.32 / -1.335 (-1.00%)
01/13/23 JPMorgan reports Q4 EPS $3.57, consensus $3.07 01/12/23 Notable companies reporting before tomorrow's open 10/14/22 JPMorgan reports Q3 EPS $3.12, consensus $2.88 01/30/23 GE HealthCare sees FY23 adjusted EPS $3.60-$3.75 01/30/23 GE HealthCare reports Q4 adjusted EPS $1.31 vs. $1.36 a year ago 01/10/23 GE HealthCare sees FY23 organic revenue growth 5%-7% 01/10/23 GE HealthCare sees FY22 revenue about $18.3B 02/09/23 Cabot sees FY23 EPS $6.25-$6.75, consensus $6.51 02/09/23 Cabot reports Q1 adjusted EPS 98c, consensus 97c 11/07/22 Cabot sees FY23 adjusted EPS $6.25-$6.75, consensus $6.17 11/07/22 Cabot reports Q4 adjusted EPS $1.55, consensus $1.45 03/01/23 Horizon Therapeutics reports Q4 EPS $1.21, consensus $1.09 01/31/23 Amgen sees FY23 adjusted EPS $17.40-$18.60, consensus $18.33 01/31/23 Amgen reports Q4 adjusted EPS $4.09, consensus $4.09 01/31/23 Notable companies reporting after market close $126.90 / -1.165 (-0.91%)
02/28/23 Advance Auto Parts sees FY23 EPS $10.20-$11.20 02/28/23 Advance Auto Parts reports Q4 adjusted EPS $2.88, consensus $2.39 02/27/23 Notable companies reporting before tomorrow's open
Options
Notable gainers among…
Notable gainers among liquid option names this morning include Illumina (ILMN) $222.65 +28.64, Newmont Mining (NEM) $44.23 +2.07, Moderna (MRNA) $143.27 +4.98, Eli Lilly (LLY) $326.23 +11.21, and Crown Castle (CCI) $131.31 +4.44.
Show Hide Related Items >> <<
02/23/23 Newmont announces new dividend structure 02/23/23 Newmont reports FY22 attributable gold ounces of 96.1M vs. 92.8M last year 02/23/23 Newmont declares 40c per share dividend 02/23/23 Newmont sees FY23 gold production 5.7M-6.3M ounces 03/10/23 Moderna expands U.S. presence, plans to hire 2,000 by end of 2023 02/23/23 Moderna says $2.8B remaining under latest buyback authorization 02/23/23 Moderna backs forecast of $5B in COVID-19 sales contracted for 2023 delivery 02/23/23 Moderna sees FY23 CapEx at about $1.0B and R&D expense at about $4.5B $322.45 / +7.505 (+2.38%)
03/08/23 Eli Lilly says primary, secondary endpoints not met in A4 Study 03/08/23 Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older 03/03/23 Eli Lilly says FDA broadens indication for Verzenio 03/01/23 Eli Lilly cuts insulin prices by 70%, caps out of pocket costs $217.36 / +23.24 (+11.97%)
03/02/23 Myriad Genetics, Illumina expand partnership for HRD testing access 03/02/23 Illumina and Myriad Genetics partner for HRD testing in the U.S. 02/02/23 Guardant Health 'pleased' with ruling in Illumina case 02/01/23 Illumina appoints Joydeep Goswami as CFO 01/09/23 Crown Castle announces proposed offering of senior notes 11/20/22 Fly Intel: Top five weekend stock stories 10/24/22 Crown Castle director buys $150.4K in common stock 10/19/22 Crown Castle increases quarterly dividend 6.5% to $1.57 per share $217.36 / +23.24 (+11.97%)
03/13/23 Piper Sandler Piper agrees with Icahn, says Illumina base business undervalued 02/14/23 UBS Illumina price target lowered to $240 from $255 at UBS 02/08/23 Stifel Illumina price target lowered to $235 from $285 at Stifel 02/08/23 RBC Capital Illumina price target raised to $303 from $284 at RBC Capital 02/24/23 TD Securities Newmont upgraded to Buy at TD Securities following 20% correction 02/24/23 TD Securities Newmont upgraded to Buy from Hold at TD Securities 02/16/23 Jefferies Newcrest Mining downgraded to Hold from Buy at Jefferies 02/14/23 UBS UBS downgrades Newmont ahead of expected dividend cut 03/13/23 TD Cowen Moderna upgraded to Outperform from Market Perform at TD Cowen 03/07/23 TD Cowen Moderna sees several disease growth opportunities, says TD Cowen 03/01/23 RBC Capital Moderna initiated with an Outperform at RBC Capital 02/28/23 Deutsche Bank Moderna price target lowered to $200 from $225 at Deutsche Bank $322.45 / +7.505 (+2.38%)
03/13/23 Wells Fargo Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo 03/09/23 JPMorgan Eli Lilly weakness brings attractive entry point, says JPMorgan 03/06/23 Jefferies Jefferies starts 'priced to perfection' Eli Lilly with a Hold 01/31/23 RBC Capital Crown Castle price target raised to $162 from $150 at RBC Capital 01/27/23 TD Cowen Crown Castle price target raised to $152 from $149 at Cowen 01/23/23 KeyBanc Crown Castle downgraded to Sector Weight from Overweight at KeyBanc 01/13/23 Truist Crown Castle price target lowered to $175 from $230 at Truist 02/23/23 Newmont: Sustaining capital seen at $1-$1.2B per year over 5 year period 02/23/23 Newmont reports Q4 EPS 44c, consensus 46c 11/01/22 Newmont reports Q3 adjusted EPS 27c, consensus 50c 02/23/23 Moderna reports Q4 EPS $3.61, consensus $4.67 02/22/23 Notable companies reporting before tomorrow's open 11/03/22 Moderna reports Q3 EPS $2.53, consensus $3.29 $322.45 / +7.505 (+2.38%)
03/09/23 Precision BioSciences reports Q4 EPS (26c), consensus (21c) 02/02/23 Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30 02/02/23 Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78 02/01/23 Notable companies reporting before tomorrow's open $217.36 / +23.24 (+11.97%)
02/07/23 Illumina sees FY23 adjusted EPS $1.25-$1.50, consensus $1.98 02/07/23 Illumina reports Q4 adjusted EPS 14c, consensus 10c 02/07/23 Notable companies reporting after market close 11/03/22 Illumina sees FY22 adjusted EPS $2.35-$2.50, consensus $2.78 01/25/23 Crown Castle backs FY23 AFFO view $7.58-$7.68, consensus $7.63 01/25/23 Crown Castle reports Q4 AFFO $1.85, consensus $1.83 10/19/22 Crown Castle backs FY22 AFFO view $7.31-$7.41, consensus $7.36 10/19/22 Crown Castle sees FY23 AFFO $7.63, consensus $7.54 10/15/22 BHP among mining stocks with bright long-term outlook, Barron's says 09/17/22 Newmont stock too cheap to ignore, Barron's says 03/07/23 Moderna CEO pushes back on pricing plans for Covid-19 shot, WSJ reports 02/15/23 Moderna plans to keep COVID vaccine free for consumers, ABC News says 02/15/23 Sanders calls Moderna chief to testify on vaccine price hike plans, WP says 02/01/23 Novavax refuses to refund $700M for COVID shots never delivered, NY Times says $322.45 / +7.505 (+2.38%)
03/06/23 New diabetes drugs altering how patients are treated, WSJ reports 12/19/22 Eli Lilly's Mounjaro, Trulicity added to FDA shortage list, STATNews reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 10/11/22 New quality issues found at Eli Lilly drug plant, Reuters reports $217.36 / +23.24 (+11.97%)
03/13/23 Icahn planning proxy fight at Illumina, WSJ reports 01/11/23 Illumina to face EU fine of 10% of turnover due to Grail deal, Reuter says 01/11/23 Illumina facing EU fine of 10% turnover over Grail deal, Reuters says 10/08/22 Illumina should be bought before stock drives higher, Barron's says 11/19/22 Cell-tower REITs could climb 20%, time to buy American and SBA, Barron's says 02/06/23 What You Missed On Wall Street On Monday 02/06/23 What You Missed On Wall Street This Morning 02/06/23 Fly Intel: Pre-market Movers 03/07/23 What You Missed On Wall Street On Tuesday 03/07/23 What You Missed On Wall Street This Morning 02/24/23 What You Missed On Wall Street On Friday 02/24/23 What You Missed On Wall Street This Morning $322.45 / +7.505 (+2.38%)
03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning $217.36 / +23.24 (+11.97%)
03/13/23 Fly Intel: Pre-market Movers 02/07/23 Fly Intel: After-Hours Movers 02/03/23 Sell these stocks now, proven algorithm says 01/11/23 What You Missed On Wall Street On Wednesday 03/10/23 Newmont Mining call volume above normal and directionally bullish 03/10/23 Early notable gainers among liquid option names on March 10th 02/23/23 Unusually active option classes on open February 23rd 02/06/23 Unusually active option classes on open February 6th 01/30/23 Moderna put volume heavy and directionally bearish 01/18/23 Early notable gainers among liquid option names on January 18th 01/18/23 Unusually active option classes on open January 18th $322.45 / +7.505 (+2.38%)
11/01/22 Unusually active option classes on open November 1st 10/03/22 Eli Lilly And Co put volume heavy and directionally bearish $217.36 / +23.24 (+11.97%)
02/13/23 Early notable gainers among liquid option names on February 13th 02/07/23 Illumina options imply 6.4% move in share price post-earnings 10/04/22 Early notable gainers among liquid option names on October 4th 09/28/22 Early notable gainers among liquid option names on September 28th 12/22/22 Early notable gainers among liquid option names on December 22nd 10/19/22 Crown Castle options imply 3.4% move in share price post-earnings
Upgrade
Wells Fargo upgraded Eli…
Wells Fargo upgraded Eli Lilly to Overweight from Equal Weight with a price target of $375, up from $360. The recent weakness in the shares creates a buying opportunity as Lilly's fundamentals remain the same, the analyst tells investors in a research note. As current share levels, the risk/reward into the donanemab Alzheimer's trial "may be skewed to the upside," contends the firm. Wells says the stock is down 18% from its peak without any fundamental change. This is a good opportunity to own the highest growth stock in the large pharma sector, it writes.
Show Hide Related Items >> <<
03/08/23 Eli Lilly says primary, secondary endpoints not met in A4 Study 03/08/23 Eli Lilly: FDA accepts sNDA for Jardiance for children 10 years and older 03/03/23 Eli Lilly says FDA broadens indication for Verzenio 03/01/23 Eli Lilly cuts insulin prices by 70%, caps out of pocket costs 03/13/23 Wells Fargo Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo 03/09/23 JPMorgan Eli Lilly weakness brings attractive entry point, says JPMorgan 03/06/23 Jefferies Jefferies starts 'priced to perfection' Eli Lilly with a Hold 03/06/23 Jefferies Eli Lilly initiated with a Hold at Jefferies 03/09/23 Precision BioSciences reports Q4 EPS (26c), consensus (21c) 02/02/23 Eli Lilly raises FY23 adjusted EPS view to $8.35-$8.55 from $8.10-$8.30 02/02/23 Eli Lilly reports Q4 adjusted EPS $2.09, consensus $1.78 02/01/23 Notable companies reporting before tomorrow's open 03/06/23 New diabetes drugs altering how patients are treated, WSJ reports 12/19/22 Eli Lilly's Mounjaro, Trulicity added to FDA shortage list, STATNews reports 10/20/22 Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports 10/11/22 New quality issues found at Eli Lilly drug plant, Reuters reports 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 What You Missed On Wall Street On Thursday 02/02/23 What You Missed On Wall Street This Morning 03/10/23 Early notable gainers among liquid option names on March 10th 11/01/22 Unusually active option classes on open November 1st 10/03/22 Eli Lilly And Co put volume heavy and directionally bearish 09/28/22 Early notable gainers among liquid option names on September 28th
